5.00
-0.59 (-10.55%)
| 前收盘价格 | 5.59 |
| 收盘价格 | 5.58 |
| 成交量 | 198,051 |
| 平均成交量 (3个月) | 166,850 |
| 市值 | 180,311,840 |
| 价格/销量 (P/S) | 51.55 |
| 股市价格/股市净资产 (P/B) | 6.50 |
| 52周波幅 | |
| 利润日期 | 6 Nov 2025 |
| 营业利益率 (TTM) | -3,917.27% |
| 稀释每股收益 (EPS TTM) | -3.47 |
| 季度收入增长率 (YOY) | -27.40% |
| 总债务/股东权益 (D/E MRQ) | 4.68% |
| 流动比率 (MRQ) | 3.67 |
| 营业现金流 (OCF TTM) | -67.20 M |
| 杠杆自由现金流 (LFCF TTM) | -48.03 M |
| 资产报酬率 (ROA TTM) | -135.31% |
| 股东权益报酬率 (ROE TTM) | -263.65% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Instruments & Supplies (US) | 看涨 | 混合的 |
| Medical Instruments & Supplies (全球的) | 看涨 | 混合的 | |
| 股票 | Anteris Technologies Global Cor | 混合的 | - |
AIStockmoo 评分
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | -1.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -2.5 |
| 平均 | 0.25 |
|
Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. Its product, the DurAVR THV system, represents a product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Its DurAVR THV system consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. |
|
| 部门 | Healthcare |
| 行业 | Medical Instruments & Supplies |
| 投资方式 | Small Value |
| 内部持股比例 | 0.21% |
| 机构持股比例 | 64.12% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| L1 Capital Pty Ltd | 30 Jun 2025 | 2,812,000 |
| Rhenman & Partners Asset Management Ab | 30 Jun 2025 | 1,250,763 |
| One68 Global Capital, Llc | 31 Mar 2025 | 308,523 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合